Healthcare Stock Bets on GenAI and Outcome-Based Deals: Can New Technology Platforms Unlock Its $135 Billion Market Opportunity?
The global life sciences industry is increasingly adopting technology and outsourcing to improve operational efficiency, reduce costs and accelerate drug commercialisation. Indegene is positioning itself to capitalise on this shift through its healthcare expertise, GenAI platforms and outcome-based service offerings.
With a market capitalisation of Rs. 14,879 cr, Indegene Limited's shares were trading at Rs. 618 per share, down from its previous close of Rs. 622.95 per share. It has delivered a return of 20 percent in a year.
Also Read: L&T Heavy Civil Infrastructure Wins Noida Metro Aqua Line Extension Order For 15.1 Km Viaduct And 10 Stations
Rising demand for technology-based life sciences services
The life sciences sector worldwide is undergoing a major change because of increased digitisation, increasing demand for outsourcing, and complex operations in the pharmaceutical industry. Pharmaceutical companies have started realising the need to be more efficient in their operations and launch their drugs faster while keeping an eye on regulatory issues and controlling their costs. The rise in the above trend has resulted in creating various opportunities for technology-based service providers having a combination of healthcare and technology expertise.
One such example is Indegene Ltd., working at the convergence of technology and healthcare. Having 27+ years of presence in the life sciences sector, Indegene Ltd. offers various services in areas of medical affairs, commercial operations, regulatory writing, pharmacovigilance, content management, and digital transformation.
$135 billion market opportunity
Indegene estimates its total addressable market at more than $135 billion, covering several operational segments across the life sciences industry. These include marketing and sales, regulatory and medical affairs, pharmacovigilance, drug discovery and clinical trials, manufacturing, supply chain and distribution.
Marketing and sales account for approximately $55 billion of this opportunity, while regulatory and medical affairs contribute $24 billion. Pharmacovigilance represents another $21 billion, followed by drug discovery and clinical trials at $36 billion. Manufacturing, supply chain and distribution account for the remaining $21 billion.
Outsourcing in these verticals is expected to grow at a compound annual growth rate of 9-14% from 2022 to 2026. The trend towards the greater use of technology, patent expiry, pricing pressure, and the requirement to commercialise existing drug pipelines are making pharmaceutical companies look into outsourcing specialised functions.
GenAI platforms to drive the next phase of growth
One of the key strategies for Indegene is the integration of Generative AI (GenAI) in the existing services of the company as well as creation of novel technology platforms. Indegene implements a two-front strategy involving extension of its products with AI features and development of GenAI-native products for the needs of the future.
The existing platforms of Indegene include NCCA, the solution for intelligent authoring of commercial content; NAEM, the AI/ML-based case processing platform for pharmacovigilance; and MLR, the system for automating medical and regulatory content review. Indegene is working on the enhancement of the capabilities of those solutions for processing more types of content and assets, and enabling more workflows.
In the area of novel products, Indegene is developing Cortex, the integrated knowledge engineering platform based on intelligent multi-agent orchestration. In addition, Indegene has launched the Content Super App, the GenAI-native platform for pharmaceutical content that allows teams to plan, author, adapt and optimise content assets via a conversational workspace.
Additionally, its Medical Writing Platform uses AI to assist medical writers in generating initial drafts of regulatory documents more efficiently. These solutions aim to reduce turnaround times, improve productivity and enable pharmaceutical companies to manage increasingly complex workflows.
Also Read: Axiom Gas Engineering H1: Net Profit slips 53.9% YoY To ₹2.44 Cr As Revenue Falls 19%
Outcome-based deals and enterprise transformation
Another important aspect of Indegene's business model is its focus on outcome-based engagements rather than traditional time-and-material or fixed-employee contracts. According to the company, more than 60% of its revenue is outcome-aligned, including output-based engagements and managed services components in hybrid contracts.
Under this model, clients pay for the work delivered and the value created rather than simply the number of employees deployed. This allows Indegene to benefit from productivity improvements while helping clients achieve better cost efficiency and faster execution.
The company's Q2 FY27 presentation highlighted several enterprise engagements where it expanded its scope from individual technology implementations to integrated operating model mandates. For instance, an Agentic AOR pilot for a large pharmaceutical company was scaled into a full-scale engagement, reducing content creation timelines from months to days.
In another engagement, a change-management consulting assignment with a top 20 pharmaceutical company expanded into a full operating model mandate within one quarter. The company also established a global content factory across commercial and medical content for a top pharmaceutical company's international business. These developments demonstrate its strategy of increasing wallet share within existing accounts through integrated services.
Q2 FY27 Financial Performance
Indegene reported strong revenue growth during the second quarter of FY27, supported by deeper client relationships, new customer additions and increasing demand for its technology-led services.
Revenue from operations increased to Rs. 1,122.3 crore from Rs. 804.2 crore in the corresponding quarter last year. EBITDA rose 32% to Rs. 187.3 crore, while profit after tax increased 10% to Rs. 112.3 crore. However, EBITDA margin declined to 16.7% from 17.6% a year ago, reflecting cost pressures and the impact of the annual wage increase.
Also read: Pharma Stock Signals Upside After Ascending Triangle Pattern Emerges on Its Chart
For the first half of FY27, revenue stood at Rs. 2,185.4 crore, registering year-on-year growth of 39.6% in rupee terms and 27% in US dollar terms. Management expects EBITDA to grow faster than revenue in the coming quarters as the wage increase is fully absorbed and productivity improvements, operating leverage and new deal ramp-ups contribute to profitability.
The company also expects higher investment yields and lower amortisation expenses to support profit margin expansion. The company indicated that depreciation and amortisation could reduce by Rs. 56 million per quarter in Q3 and Q4 FY27 compared with Q2.
Expanding customer relationships and global presence
Indegene is also witnessing growth in its customer base and deeper engagement with existing pharmaceutical clients. Its active client relationships increased to 107 in Q2 FY27 from 76 in the corresponding quarter last year, representing growth of 40.8%. The number of clients generating more than $1 million in revenue increased to 59 from 40 a year ago.
Furthermore, its top 10 clients grew 13.5% sequentially, while revenue from the top 20 clients stood at Rs. 755.2 crore. The company serves 25.3% of the global top 10 pharmaceutical companies and 56.3% of the global top 20 pharmaceutical companies.
Geographically, North America contributed 74.5% of Q2 FY27 revenue, followed by Europe at 22.9%. Biopharma remained the largest customer industry, contributing 91.8% of revenue, while medical devices and emerging biotechnology contributed 3% and 3.2%, respectively.
Outlook and key factors to watch
Moving forward, the success of Indegene's future growth will rely on its ability to turn its GenAI investments into commercial engagements, scale its enterprise platforms and develop relationships with its existing clients. Its estimated addressable market of $135 billion, customer growth and involvement in the pharma outsourced services will give potential growth avenues.
Nevertheless, investors need to track its ability to sustain revenue growth with margin improvement. The effect of wage hikes, increased operating costs, technology investments and dependency on the biopharma industry and North American region will be key variables that investors should look out for.
Overall, Indegene aims at establishing itself beyond the conventional life sciences outsourcing through a combination of its domain expertise, GenAI platforms and outcome-focused engagements. It needs to capitalise on its technology investments, enterprise engagements and sustain its revenue growth with profitability to realise its estimated $135 billion market opportunity.
Also Read: IOB Special Fixed Deposit: ₹10 Lakh Deposit Can Earn Up to ₹6,006 Monthly - Check Rates & Rules